A Prospective Cohort study Assessing the Body Weight Changes in Patients with Moderate to Severe Inflammatory Bowel Diseases Initiating Biologic Therapy
Latest Information Update: 09 Jul 2020
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease; Irritable bowel syndrome; Ulcerative colitis
- Focus Adverse reactions
- 09 Jul 2020 New trial record
- 19 May 2020 Results published in Gastroenterology in conjunction with Digestive Disease Week 2020